Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd

Dr Mekhail discusses the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma.

Discover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.

Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.

Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.

Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.

Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.

Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.

Explore the complexity of uncommon EGFR mutations in lung cancer with experts discussing classifications, testing methodologies, and the necessity of comprehensive panels for accurate identification.

Delve into the evolving landscape of treating EGFR mutations in lung cancer, exploring emerging therapies, structural classifications, and the complexity of individual mutation responses.

The impact of and strategies for addressing less frequent mutations in NSCLC treatment decisions, emphasizing actionable alterations and timely interventions in challenging scenarios.

Expert perspectives on improving turnaround times in genomic testing for lung cancer, covering strategies, challenges, and the significance of liquid biopsy in optimizing patient care.

Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.

Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.

Explore the latest breakthroughs in precision medicine with a focus on biomarker testing and emerging targets in patients with non–small cell lung cancer.

Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd, discusses the prevalence of uncommon EGFR mutations in patients with lung cancer, research needs for these patients, and how the findings from the phase 3 LUX-Lung 3 and LUX-Lung 6 trials support the use of afatinib in this population.